<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="section" /><meta name="keywords" content="Beclometasone dipropionate: asthma; Budesonide: asthma; Fluticasone propionate: asthma; Mometasone: asthma; Symbicort; Chlorofluorocarbon propellants; CFC see Chlorofluorocarbon propellants; Hydrofluoroalkane propellants; HFA see Hydrofluoroalkane propellants" /><meta name="IX" content="Beclometasone dipropionate: asthma; Budesonide: asthma; Fluticasone propionate: asthma; Mometasone: asthma; Symbicort; Chlorofluorocarbon propellants; Hydrofluoroalkane propellants" /><meta name="IXN" content="CFC see Chlorofluorocarbon propellants; HFA see Hydrofluoroalkane propellants" /><title>3.2 Corticosteroids: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="2985.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="2985.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=2985.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="1008.htm">3 Respiratory system</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="2983.htm" title="Previous: Nebuliser diluent">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="2986.htm" title="Next: BECLOMETASONE DIPROPIONATE">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_2985">3.2 Corticosteroids</h1><?highlighter on?><div id="pC" class="jN"><div class="cAJ"><span class="cAD">Additional information</span> interactions (<a href="41001i484.htm" title="Go to appendix 1">Corticosteroids</a>).</div><div><p>Corticosteroids are used for the management
of reversible and irreversible airways disease. An inhaled corticosteroid
used for 3–4 weeks may help to distinguish asthma from chronic obstructive
pulmonary disease; clear improvement over 3–4 weeks suggests asthma. </p><div class="cAZ" id="_202648"><h2>Asthma</h2> <p class="cAX">Corticosteroids are effective in <i>asthma</i>; they reduce airway inflammation (and hence reduce
oedema and secretion of mucus into the airway).</p><p>An inhaled <span>corticosteroid</span> is used regularly
for prophylaxis of asthma when patients require a beta<sub>2</sub> agonist more than twice a week, or if symptoms disturb sleep more
than once a week, or if the patient has suffered exacerbations in
the last 2 years requiring a systemic corticosteroid or a nebulised
bronchodilator (see <a title="topic: MANAGEMENT OF CHRONIC ASTHMA IN ADULTS AND CHILDREN" href="119630.htm#_119630">Management of Chronic Asthma
table</a>). <i>Regular use</i> of inhaled corticosteroids reduces the risk
of exacerbation of asthma.</p><p>Current and previous smoking reduces the effectiveness of inhaled
corticosteroids and higher doses may be necessary.</p><p>Corticosteroid inhalers must be used regularly for maximum benefit;
alleviation of symptoms usually occurs 3 to 7 days after initiation. <b>Beclometasone dipropionate</b>, <b><span>budesonide</span></b>, <b><span>fluticasone propionate</span></b>, and <b><span>mometasone
furoate</span></b> appear to be equally effective. Preparations that combine a corticosteroid
with a long-acting beta<sub>2</sub> agonist may be helpful for patients
stabilised on the individual components in the same proportion.</p> <p class="cAX">In adults using
an inhaled corticosteroid and a long-acting beta<sub>2</sub> agonist
for the prophylaxis of asthma, but who are poorly controlled, (see
step 3 of the <a title="topic: Management of chronic asthma in adults and children" href="119630.htm#_119630">Management of Chronic Asthma
table</a>) <span class="cZ">Symbicort</span>® (budesonide with formoterol) can be used as a reliever (instead
of a short-acting beta<sub>2</sub> agonist), in addition to its regular
use for the prophylaxis of asthma. <span class="cZ">Symbicort</span>® can
also be used in this way in adults using an inhaled corticosteroid
with a dose greater than beclometasone dipropionate 400 micrograms
daily<sup class="footnote"><a title="Go to footnote" href="2985.htm#footnote202647">(1)</a></sup>, but who are
poorly controlled (see step 2 of the <a title="BNF:topic: Management of chronic asthma" href="119630.htm#_119630">Management of Chronic Asthma
table</a>). When starting this treatment,
the total regular daily dose of inhaled corticosteroid should not
be reduced. Patients must be carefully instructed on the appropriate
dose and management of exacerbations before initiating this therapy,
see <span class="cZ"><a title="BNF:preparation: Symbicort®" href="201441.htm#_201441">Symbicort</a></span>®. Patients using budesonide with formoterol
as a reliever once a day or more should have their treatment reviewed
regularly. This management approach is also used by some specialists
in children 12–18 years [unlicensed]. It has not been investigated
with combination inhalers containing other corticosteroids and long-acting
beta<sub>2</sub> agonists.</p><p>High doses of inhaled corticosteroid can be prescribed
for patients who respond only partially to standard doses with a long-acting
beta<sub>2</sub> agonist or another long-acting bronchodilator (see <a title="topic: MANAGEMENT OF CHRONIC ASTHMA IN ADULTS AND CHILDREN" href="119630.htm#_119630">Management of Chronic Asthma
table</a>).
High doses should be continued only if there is clear benefit over
the lower dose. The recommended maximum dose of an inhaled corticosteroid
should not generally be exceeded. However, if a higher dose is required,
then it should be initiated and supervised by a specialist. The use
of high doses of inhaled corticosteroid can minimise the requirement
for an oral corticosteroid.</p><p>Systemic corticosteroid therapy may be necessary during episodes
of stress, such as severe infection, or if the asthma is worsening,
when higher doses are needed and access of inhaled drug to small airways
may be reduced; patients may need a reserve supply of corticosteroid
tablets.</p></div><div class="cAZ"><h2>Chronic obstructive pulmonary disease</h2> <p class="cAX">In <i>chronic obstructive pulmonary disease</i> inhaled corticosteroid
therapy may reduce exacerbations when given in combination with an
inhaled long-acting beta<sub>2</sub> agonist, see <a title="BNF:topic: Chronic obstructive pulmonary disease" href="100062.htm#_100062">section 3.1</a>.</p></div><div id="_2985.2"><div class="cAZ" id="_203929"><h2>Cautions of inhaled <span>corticosteroids</span></h2> <p class="cAX">Inhaled corticosteroids should be used with caution in patients
with systemic infection, see Infections (<a title="BNF:sub-topic: Infections" href="106139.htm#_106139">section 6.3.2</a>).</p><div><h3 class="cAE">Paradoxical bronchospasm</h3> <p class="cAE">The <span id="_201969">potential for paradoxical bronchospasm (calling for
discontinuation and alternative therapy) should be borne in mind</span>—mild bronchospasm may be prevented by inhalation of
a short-acting beta<sub>2</sub> agonist beforehand (or by transfer
from an aerosol inhalation to a dry powder inhalation).</p></div><div style="margin-top: 1em"><h3 class="cAE">CFC-free inhalers</h3> <p class="cAE">Chlorofluorocarbon (CFC) propellants in pressurised
aerosol inhalers have been replaced by hydrofluoroalkane (HFA)
propellants.</p></div><p>Doses for corticosteroid CFC-free pressurised
metered-dose inhalers may be different from traditional CFC-containing
inhalers and may differ between brands, see MHRA/CHM advice below. </p><p>For <b>interactions:</b> see Appendix 1 (corticosteroids)</p><div class="cN"><h3 class="cBP">MHRA/CHM advice (July 2008)</h3><ul class="cBF"><li><p class="cQ">Beclometasone dipropionate CFC-free pressurised metered-dose
inhalers (<span class="cZ">Qvar</span>® and <span class="cZ">Clenil Modulite</span>®) are <b>not</b> interchangeable and should be prescribed
by brand name; <span class="cZ">Qvar</span>® has extra-fine particles,
is more potent than traditional beclometasone dipropionate CFC-containing
inhalers, and is approximately twice as potent as <span class="cZ">Clenil
Modulite</span>®;</p></li><li><p class="cQ"><span class="cZ">Fostair</span>® is a combination beclometasone
dipropionate and formoterol fumarate CFC-free pressurised metered-dose
inhaler; <span class="cZ">Fostair</span>® has extra-fine particles and
is more potent than traditional beclometasone dipropionate CFC-free
inhalers.</p></li></ul></div></div></div><div id="_2985.1"><div class="cAZ"><h2>Side-effects of inhaled <span>corticosteroids</span></h2> <p class="cAX">Inhaled <span>corticosteroids</span> have considerably
fewer systemic effects than oral <span>corticosteroids</span> (<a title="topic: Disadvantages of corticosteroids" href="4256.htm#_4256">section 6.3.2</a>), but adverse effects have been
reported.</p><p>High doses of inhaled <span>corticosteroids</span> (see <a title="topic: Management of chronic asthma in adults and children" href="119630.htm#_119630">Management of Chronic Asthma
table</a>)
used for prolonged periods can induce adrenal suppression. Inhaled
corticosteroids have been associated with adrenal crisis and coma
in children; excessive doses should be <b>avoided</b>. Patients
using high doses of inhaled corticosteroids should be given a ‘steroid
card’ (<a title="topic: Steroid treatment card" href="119642.htm#_119642">section 6.3.2</a>) and specific written advice
to consider corticosteroid replacement during an episode of stress, such as severe intercurrent illness
or an operation.</p><p>High doses of inhaled corticosteroid have been
associated with lower respiratory tract infections, including pneumonia,
in older patients with chronic obstructive pulmonary disease.</p><p>Bone mineral density may be reduced following long-term inhalation
of higher doses of <span>corticosteroids</span>, predisposing
patients to osteoporosis (<a title=" Drugs affecting bone metabolism" href="4439.htm#_4439">section 6.6</a>). It is therefore sensible to ensure
that the dose of an inhaled corticosteroid is no higher than necessary
to keep a patient’s asthma under good control.</p><p>In children, growth restriction associated with systemic corticosteroid
therapy does not seem to occur with recommended doses of inhaled therapy;
although initial growth velocity may be reduced, there appears to
be no effect on achieving normal adult height. However, the height of children receiving prolonged treatment of inhaled corticosteroid
should be monitored; if growth is slowed, referral to a paediatrician
should be considered. Large-volume spacer devices should
be used for administering inhaled <span>corticosteroids</span> in children under 15 years (<a title="target-block: NICE for drug delivery devices" href="2956.htm#_2956.1">see NICE guidance, section
3.1.5</a>); they are also useful in older children and adults,
particularly if high doses are required. Spacer devices increase airway
deposition and reduce oropharyngeal deposition.</p><p>A small risk of glaucoma with prolonged high doses of inhaled
corticosteroids has been reported. Hoarseness, throat irritation,
dysphonia, and candidiasis of the mouth or throat may occur with inhaled
corticosteroids (see also below). Hypersensitivity reactions (including
rash and angioedema) have been reported rarely. Paradoxical bronchospasm
has been reported very rarely. Anxiety, depression, sleep disturbances,
and behavioural changes including hyperactivity, irritability, and
aggression (particularly in children), hyperglycaemia, cataracts,
skin thinning and bruising have also been reported.</p><div><h3 class="cAE">Candidiasis</h3> <p class="cAE">The risk of oral candidiasis can be reduced by using a spacer
device with the corticosteroid inhaler; rinsing the mouth with water
(or cleaning a child’s teeth) after inhalation of a dose may also
be helpful. Antifungal oral suspension or oral gel (<a title="sub-section: Oropharyngeal anti-infective drugs" href="5701.htm#_5701">section 12.3.2</a>) can
be used to treat oral candidiasis without discontinuing therapy.</p></div></div></div><div class="cAZ"><h2>Oral</h2> <p class="cAX">An acute attack of asthma should be treated
with a short course of an oral <span>corticosteroid</span> starting
with a high dose, see <a title="BNF:topic: Management of acute asthma" href="119631.htm#_119631">Management of Acute Asthma table</a>. Patients whose asthma has
deteriorated rapidly usually respond quickly to <span>corticosteroids</span>. The dose can usually be stopped abruptly; tapering is not needed
provided that the patient receives an inhaled corticosteroid in an
adequate dose (apart from those on maintenance oral corticosteroid
treatment or where oral corticosteroids are required for 3 or more
weeks); see also Withdrawal of <span>Corticosteroids</span>, <a title="BNF:sub-topic: Withdrawal of corticosteroids" href="200131.htm#_200131">section 6.3.2</a>. In
patients who have needed several courses of oral corticosteroids and
in whom the possibility of a period on maintenance corticosteroids
is being considered, it may be useful to taper the corticosteroid
dose gradually to identify a threshold dose for asthma control. This
should only be done after other standard options for controlling asthma
have been tried (see the <a title="BNF:topic: Management of chronic asthma" href="119630.htm#_119630">Management of Chronic Asthma
table</a>).</p><p>In chronic asthma, when the response to other drugs has been
inadequate, longer term administration of an oral <span>corticosteroid</span> may be necessary; in such cases high doses of an inhaled corticosteroid
should be continued to minimise oral corticosteroid requirements,
see <a title="BNF:topic: Management of chronic asthma" href="119630.htm#_119630">Management of Chronic Asthma
table</a>. Patients taking long-term
oral <span>corticosteroids</span> for asthma can often be transferred
to an inhaled corticosteroid but the transfer must be slow, with gradual
reduction in the dose of the oral corticosteroid, and at a time when
the asthma is well controlled.</p><p> During an acute exacerbation of chronic obstructive pulmonary
disease, <span>prednisolone</span> 30 mg daily should be given
for 7–14 days; treatment can be stopped abruptly. Prolonged treatment
with oral <span>prednisolone</span> is of no benefit and maintenance
treatment is not normally recommended.</p><p>An oral <span>corticosteroid</span> should normally be
taken as a single dose in the morning to reduce the disturbance to
circadian cortisol secretion. Dosage should always be titrated to
the lowest dose that controls symptoms. Regular peak-flow measurements
help to optimise the dose.</p></div><div class="cAZ"><h2>Parenteral</h2> <p class="cAX">For the use of <span>hydrocortisone</span> injection in the emergency treatment of acute severe asthma, see <a title="topic: MANAGEMENT OF ACUTE SEVERE ASTHMA IN GENERAL PRACTICE" href="119631.htm#_119631">Management of Acute Asthma
table</a>.</p></div></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_2986"><a href="2986.htm" title="BECLOMETASONE DIPROPIONATE">BECLOMETASONE DIPROPIONATE</a></li><li id="_2999"><a href="2999.htm" title="BUDESONIDE">BUDESONIDE</a></li><li id="_201431"><a href="201431.htm" title="BUDESONIDE WITH FORMOTEROL FUMARATE">BUDESONIDE WITH FORMOTEROL FUMARATE</a></li><li id="_129218"><a href="129218.htm" title="CICLESONIDE">CICLESONIDE</a></li><li id="_3004"><a href="3004.htm" title="FLUTICASONE PROPIONATE">FLUTICASONE PROPIONATE</a></li><li id="_213697"><a href="213697.htm" title="FLUTICASONE PROPIONATE WITH SALMETEROL">FLUTICASONE PROPIONATE WITH SALMETEROL</a></li><li id="_127924"><a href="127924.htm" title="MOMETASONE FUROATE">MOMETASONE FUROATE</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="2983.htm">Previous: Nebuliser diluent</a> | <a class="top" href="2985.htm#">Top</a> | <a accesskey="]" href="2986.htm">Next: BECLOMETASONE DIPROPIONATE</a> ►</div><div class="cF"><div class="footnote" id="footnote202647"><sup>(1)</sup>For standard doses of other inhaled corticosteroids, see <a title="BNF:topic: Management of chronic asthma" href="119630.htm#_119630">Management of Chronic Asthma
table</a>.</div></div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>